Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and bevacizumab in advanced hepatocellular carcinoma
NCT03382886Phase 1Terminated
- Sponsor
- University of Utah
- Start
- Apr 2018
- Primary completion
- Jul 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of nivolumab in hepatocellular carcinoma (HCC), sponsored by University of Utah. Primary endpoint: Adverse Events at 2 years. Started Apr 2018; status: terminated.
02
Drugs
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03382886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03382886.